Toth Financial Advisory Corp Has $539,000 Stock Position in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)

Toth Financial Advisory Corp raised its position in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) by 1,252.0% in the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 33,800 shares of the biopharmaceutical company’s stock after acquiring an additional 31,300 shares during the period. Toth Financial Advisory Corp’s holdings in Catalyst Pharmaceuticals were worth $539,000 as of its most recent SEC filing.

Several other large investors have also recently added to or reduced their stakes in the company. Parkside Financial Bank & Trust bought a new stake in shares of Catalyst Pharmaceuticals in the 4th quarter valued at approximately $31,000. GAMMA Investing LLC grew its stake in shares of Catalyst Pharmaceuticals by 72.9% in the 1st quarter. GAMMA Investing LLC now owns 1,942 shares of the biopharmaceutical company’s stock valued at $31,000 after purchasing an additional 819 shares during the period. Nisa Investment Advisors LLC grew its stake in shares of Catalyst Pharmaceuticals by 306.3% in the 4th quarter. Nisa Investment Advisors LLC now owns 5,079 shares of the biopharmaceutical company’s stock valued at $85,000 after purchasing an additional 3,829 shares during the period. Tower Research Capital LLC TRC grew its stake in shares of Catalyst Pharmaceuticals by 84.5% in the 4th quarter. Tower Research Capital LLC TRC now owns 6,184 shares of the biopharmaceutical company’s stock valued at $104,000 after purchasing an additional 2,833 shares during the period. Finally, Sherbrooke Park Advisers LLC bought a new stake in shares of Catalyst Pharmaceuticals in the 3rd quarter valued at approximately $123,000. Institutional investors and hedge funds own 79.22% of the company’s stock.

Catalyst Pharmaceuticals Stock Performance

Shares of CPRX opened at $15.49 on Friday. The firm has a market capitalization of $1.83 billion, a price-to-earnings ratio of 28.69, a PEG ratio of 1.44 and a beta of 0.73. The business’s fifty day moving average price is $15.58 and its two-hundred day moving average price is $15.35. Catalyst Pharmaceuticals, Inc. has a 52 week low of $11.55 and a 52 week high of $17.50.

Catalyst Pharmaceuticals (NASDAQ:CPRX) last announced its quarterly earnings data on Wednesday, May 8th. The biopharmaceutical company reported $0.31 EPS for the quarter, meeting analysts’ consensus estimates of $0.31. The firm had revenue of $98.51 million for the quarter, compared to analyst estimates of $97.24 million. Catalyst Pharmaceuticals had a return on equity of 25.08% and a net margin of 15.83%. As a group, research analysts forecast that Catalyst Pharmaceuticals, Inc. will post 1.63 EPS for the current year.

Wall Street Analyst Weigh In

Several equities research analysts have recently weighed in on the company. HC Wainwright reiterated a “buy” rating and issued a $26.00 price objective on shares of Catalyst Pharmaceuticals in a research note on Monday, June 3rd. Cantor Fitzgerald restated an “overweight” rating and set a $34.00 price target on shares of Catalyst Pharmaceuticals in a research report on Friday, March 22nd. TheStreet upgraded Catalyst Pharmaceuticals from a “c+” rating to a “b” rating in a research report on Tuesday, March 12th. Bank of America began coverage on Catalyst Pharmaceuticals in a research report on Thursday, March 7th. They set a “buy” rating and a $23.00 price target on the stock. Finally, Citigroup began coverage on Catalyst Pharmaceuticals in a research report on Thursday, March 14th. They set a “buy” rating and a $27.00 price target on the stock. Six investment analysts have rated the stock with a buy rating, According to MarketBeat.com, Catalyst Pharmaceuticals has a consensus rating of “Buy” and a consensus price target of $27.80.

Insider Buying and Selling at Catalyst Pharmaceuticals

In other Catalyst Pharmaceuticals news, CEO Richard J. Daly sold 17,323 shares of the stock in a transaction on Tuesday, June 4th. The stock was sold at an average price of $15.97, for a total value of $276,648.31. Following the transaction, the chief executive officer now directly owns 234,824 shares in the company, valued at approximately $3,750,139.28. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. In other news, Director Molly Harper sold 5,333 shares of the stock in a transaction on Monday, June 3rd. The stock was sold at an average price of $16.30, for a total value of $86,927.90. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CEO Richard J. Daly sold 17,323 shares of the stock in a transaction on Tuesday, June 4th. The shares were sold at an average price of $15.97, for a total value of $276,648.31. Following the completion of the transaction, the chief executive officer now directly owns 234,824 shares in the company, valued at approximately $3,750,139.28. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 135,197 shares of company stock worth $2,169,560. Insiders own 11.00% of the company’s stock.

About Catalyst Pharmaceuticals

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.